Special topic section on health economics and public policy of Alzheimer's disease

These are undeniable statements that demonstrate the importance of the problem posed by AD and other dementing disorders. However, the burden of AD is complex, and there is growing concern that health economic researchers and policymakers are insufficiently describing the scope and magnitude of the problem both from a macroperspective and microperspective. We are now entering the 25th anniversary of the first public health and public policy advocacy efforts toward “Alzheimer’s prevention,” namely the 1992 publication of the “5-5 10-10 plan” [4]. It is worthwhile to review what has been accomplished and to identify the remaining challenges. The editors of Alzheimer’s & Dementia are therefore announcing the formation of a new Special Topic Section focused on the Health Economics and Public Policy of AD. The objective is to drive global standardization in this field and to stimulate the development of a comprehensive framework for evaluating the value of novel interventions for diagnosis, treatment, prevention, and care of individuals at elevated risk or afflicted with AD.

[1]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Neumann,et al.  The economics of mild cognitive impairment , 2013, Alzheimer's & Dementia.

[3]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[4]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[5]  L. Schneider,et al.  Defeating Alzheimer's disease and other dementias: a priority for European science and society , 2016, The Lancet Neurology.

[6]  J. Karlawish,et al.  Preference-based quality of life in patients with Alzheimer's disease , 2008, Alzheimer's & Dementia.

[7]  J. Mauskopf,et al.  A Review of the Methods Used to Estimate the Cost of Alzheimer’s Disease in the United States , 2011, American journal of Alzheimer's disease and other dementias.

[8]  G. Ohlin The Organization for Economic Cooperation and Development , 1968, International Organization.

[9]  Linus Jönsson,et al.  The Cost of Dementia in Europe , 2012, PharmacoEconomics.

[10]  H. Brodaty,et al.  ALZHEIMER'S DISEASE INTERNATIONAL , 1997, International journal of geriatric psychiatry.

[11]  B. Winblad,et al.  Application of Resource Utilization in Dementia (RUD) instrument in a global setting , 2013, Alzheimer's & Dementia.

[12]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[13]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[14]  Magda Tsolaki,et al.  Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review , 2015, Alzheimer's Research & Therapy.

[15]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[16]  Z. Khachaturian Editorial: The five-five, ten-ten plan for Alzheimer's disease , 1992, Neurobiology of Aging.

[17]  A. Wimo,et al.  The Cost of Dementia in Europe A Review of the Evidence , and Methodological Considerations , 2009 .